INTRODUCTION

In October 2005, the Pan African Society of Cardiology convened the first All Africa Workshop on Rheumatic Fever (RF) and Rheumatic Heart Disease (RHD) in Drakensberg, South Africa. The event concluded with the adoption of the Drakensberg Declaration, a statement proposing an action plan targeting RF and RHD in Africa.\(^1\)

Named the Awareness Surveillance Advocacy Prevention (ASAP) programme it emphasises four key areas, namely awareness, surveillance, advocacy, and prevention.

**Strategy of the ASAP programme in RF and RHD:**
- raise public and health professional awareness
- establish surveillance systems
- advocacy for increased resources for treatment
- promoting the prevention of RF/RHD in African nations

The ASAP programme collaborates with other similar programmes of the World Heart Federation (WHF) globally, and has also been adopted by the Inter Academy Medical Panel as one of six global programmes.

Following the Drakensberg meeting, there has been renewed interest among cardiologists, other medical and public health professionals, the community and most importantly, government to be proactive in combating RF and RHD.

**Scale of RF/RHD**

Over the last 150 years the developed world has experienced a dramatic decline in the incidence and prevalence of RF/RHD through improved living conditions and the widespread use of penicillin for the treatment of group A beta haemolytic streptococcal pharyngitis. However, developing countries, which account for 80% of the world’s population, continue to face unacceptably...
high rates of RF/RHD, making it the most common cardiovascular disease affecting children and young adults in the world.\(^{(2)}\)

Together, RF & RHD affect about 15.6 million people worldwide, 2.4 million of whom are children between five and fourteen years old in developing countries.\(^{(3)}\) Sub-Saharan Africa and South Central Asia account for the majority of cases. Almost 500,000 new cases are declared every year; RF/RHD leads to an estimated 350,000 deaths annually, and hundreds of thousands of survivors are left disabled without access to the expensive medical and surgical care that the disease requires.

It is estimated that 0.3 - 3% of those with untreated group A beta haemolytic streptococcal infection progress to develop acute rheumatic fever; and such infection may often be asymptomatic. Approximately 40 - 60% of episodes of RF result in RHD.

Africa, which contains 10% of the world’s population, has a disproportionately high share of people living with RF/RHD. In 2002, of the 2.4 million children with RF/RHD living in developing countries, nearly half (>1 million) live in sub-Saharan Africa, making the continent the major hotspot of RF/RHD.\(^{(3)}\) RF is a disease of poverty; it is particularly rampant in low-income, overcrowded communities with poor housing conditions, poor nutrition and inadequate health services. A neglected “strep” throat (sore throat caused by streptococcal bacteria) can lead to repeated episodes of RF affecting mainly the large joints (arthritis) and the heart (carditis), causing chronic heart valve damage (RHD) which may necessitate expensive heart valve surgery. The condition is usually fatal if damaged heart valves are not repaired or replaced by major open-heart surgery.

RF and RHD are among the commonest causes of cardiovascular morbidity and mortality in developing countries. RHD is the second common cause of heart failure (after hypertension) in Africans and the commonest indication for cardiac surgery in tropical Africa, accounting for nearly 60% of open heart surgery.\(^{(6)}\)

There is a paucity of information on the prevalence of RHD in South Africa. Two previous studies of the prevalence of RHD in South Africa used clinical auscultation (not echocardiography) to screen for RHD.\(^{(5,6)}\) Both studies provided an estimate of 6.9/1,000 school children, which may however be an underestimate of the prevalence of RHD among children because of the low sensitivity of the method of screening used (i.e. clinical examination) and probable absence from school of more sick children with RHD. Clearly, alternative methods of screening for RF/RHD such as mobile echocardiography would provide a more accurate estimate of the prevalence of RF/RHD in the general population. A systematic review of prevalence studies found exceptionally high rates of RHD in sub-Saharan Africa, with the highest level in Kinshasa, DRC at 14/1,000 school-aged children.\(^{(7)}\) Similar high prevalence rates have been found in Cairo, Egypt (5.1/1,000) and Addis Ababa, Ethiopia (6.4/1,000).\(^{(8)}\) More recently, an echocardiographic-based study in Mozambique reported rates of 30/1,000.\(^{(9)}\)

To date there have been no studies of the incidence of RF/RHD in Africa. Anecdotal information suggests that the incidence of RF remains quite high in South Africa and that RHD is still the leading cause of acquired heart disease in children and young adults.\(^{(10)}\) In a 2002 report from a pediatric cardiology conference, a consensus opinion was that South Africa was in the midst of an RF epidemic\(^{(11)}\) despite national guidelines and recommendations for antibiotic prevention of the disease.\(^{(12)}\) Furthermore, there appears to be underreporting of RF cases by health care professionals, and poor administration of the RF notification system. A detailed analysis of the number of RF cases reported at hospital, municipal and provincial level for a 5-year period suggested underreporting by health care professionals and poor administration of the notification system.\(^{(13)}\)

**Prevention / therapeutic options**

RF/RHD is a disease of poverty, of children, unrelated to lifestyle and killing young people in the prime productive years of their lives. Sadly, it is almost entirely preventable using demonstrated strategies that are cheap and cost-effective. Prevention efforts are most effective when supported by a comprehensive programme that includes health education for parents, children, teachers and health care providers, routine screening, availability of penicillin and maintenance of a disease registry to manage known cases. Moreover, primary and secondary prevention programmes can be implemented through the existing health care services without major additional costs.

In 1997, the South African Department of Health (DOH) released a set of national guidelines on the primary prevention and prophylaxis of RF and RHD. The guidelines were intended to facilitate a comprehensive programme for the primary and secondary prevention of RF. Targeting health workers at the primary care level, they cover interventions addressing education, living conditions, diagnosis, treatment, referral, notification, and follow-
up. An evaluation of adherence to the guidelines indicated that in addition to physician awareness and compliance with the national guideline being unsatisfactory, the method for case detection of RF was unclear. A revision of the guidelines has recently been submitted to the department of health and is awaiting approval.

Many first episodes of RF can be prevented by a simple injection of penicillin for strep sore throat (primary prevention). Even if the first episode of RF is not prevented, further episodes (which almost always lead to RHD) are entirely preventable through secondary prevention. Secondary prevention requires the delivery of regular penicillin injections to prevent further RF and worsening RHD, and is the mainstay of controlling RF/RHD. At the end of the spectrum, is the need for surgical intervention to repair scarred valves. In 2000, the average cost of operative treatment for RHD in Africa was around US$5,000; in low income countries of sub-Saharan Africa with a GNP per capita of less than US$500, such as Ghana, increasing health expenditure to address this cost would adversely affect poverty reduction strategies. Unfortunately, the downscaling of quotas for operations over the years makes it difficult to establish the true extent of the need for this procedure in South Africa.

Vaccines to prevent rheumatic fever?
The development of vaccines would represent the most ideal strategy of control to prevent group A streptococcal–related disease. Despite attempts dating back for more than 50 years, vaccination has hitherto proved impossible. Recently, concentration of efforts has been on the organism’s M Protein epitopes, the diversity of which need to be elucidated: a study is currently underway to establish the molecular epidemiology of the bacteria in Cape Town. It is thus conceivable that South Africa would play a pivotal part in clinical trials of new vaccines for group A streptococcus in the future.

Lack of attention
There has been a dearth of activity related to RHD over the past two decades in Africa and elsewhere as the attention of cardiologists has tended to focus on ischaemic heart disease, while the attention of public health practitioners has tended to focus on HIV, AIDS and TB. Hypertension, and its cardiac and cerebrovascular sequelae probably represent the major burden of cardiovascular disease in Africa, but RF/RHD is still the major cause of acquired heart disease in Africa and indeed the world. It is amongst the top three causes of heart failure in sub-Saharan Africa.

CURRENT INITIATIVES

Launch of South African demonstration site
In South Africa, the ASAP Programme has designated the Vanguard Community in Cape Town as its demonstration site. To date, the ASAP team has been conducting awareness-raising presentations amongst parents, teachers and community members. In addition, we have held seminars for health professionals to enable them to recognise and diagnose streptococcal sore throat, and make valid management decisions.

Recently, portable echocardiography had been applied in landmark papers to assess the incidence of RHD in Cambodia, Mozambique and Tonga. It is well known that Doppler echocardiography is highly sensitive in demonstrating valvular regurgitation. Using this method, the highest incidence of RHD hitherto has been demonstrated in Tonga. In addition, their findings show that auscultatory findings alone would have missed more than half of the pathological lesions as later defined by echocardiography. This obviously has great implications for a screening programme based in an area of high-prevalence, with little or no resources.

The recent acquisition of a customised mobile echo-surveillance unit has enabled the launch of the surveillance component of the programme, where approximately 4,000 school-aged participants will be screened for the prevalence of RHD. This involves a comprehensive assessment with particular attention paid to skin lesions, auscultation by a pediatric cardiologist followed by a full echocardiogram. This dataset forms part of a prospective study appraising echocardiography as a screening tool for RHD in developing countries. In addition, participants will be screened for skin conditions and referred to the appropriate clinic for follow-up. The skin assessment is also of interest following work from Australia looking at relative incidences of pharyngitis versus pyoderma in high-prevalence communities. All echocardiograms will be reviewed by a pediatric cardiologist and all cases detected will be reviewed by partners at Red Cross Hospital. It is anticipated that the results from this study, in addition to providing a comparison between auscultation and echocardiography in our setting, will add to the growing body of literature establishing the world-wide prevalence of RHD.

Establishment of a global registry for RHD
In 1972, the WHO launched a register-based programme to combat RF/RHD. Subsequently the programme was expanded and
by 1990, registers had been established in 16 countries with over one million school-going children screened yielding over 3 000 cases of RHD. However the declining rate of RHD in developed countries brought this initiative to a halt and in 2001, the WHO ceased its funding to this global programme.(20) Experience elsewhere has provided evidence of registers realising notable successes in reducing RF recurrence.(21) Thus, the absence of contemporary systematically collected data is a gap that needs to be bridged in order to effectively treat patients with RHD in developing countries, where the rate of RF/RHD has not mirrored the decline in developed countries.

A global registry was launched at the South African Heart Association Congress 2008 and will be an international collaboration within the auspices of the WHF and ASAP. The purpose of this registry is to collect data on demographic and clinical profiles of patients with RHD in low and middle-income countries. It is also important to ascertain whether differences in patient characteristics in communities have clinical relevance especially as regards outcomes, since this may impact upon management strategies within different communities and age groups. A registry should also highlight deficiencies in service delivery to the most at risk patients and therefore guide in the initiation of more specific strategies within different communities and age groups. It is envisaged that the model of surveillance and prevention of RF/RHD will be successfully established, and can be rolled out at country level in order to prevent RF among children and thus avoid RHD and cardiac surgery. Through efforts such as ASAP as well as implementation of the National Department of Health guidelines for the prevention and treatment of RF/RHD, it is certainly feasible that both RF and RHD could be eradicated from South Africa within one or two generations, mimicking the achievements made recently in Cuba.(24)

REFERENCES